The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway
Abstract
Alzheimer's disease (AD) is the progressive development of fatal neurodegenerative diseases. Owing to the unclearness of the pathogenesis of AD and the failure of the drug to cross the blood-brain barrier (BBB), there is currently a lack of effective diagnostic and therapeutic approaches in the treatment of AD. The aim of this study was to design exosomes (Exo) as a specifically designed carrier able to carry curcumin (cur) to prevent neuronal death in vitro and in vivo to alleviate the AD symptoms. Our results demonstrated that Exo improved the solubility and bioavailability of cur and increased drug penetration across the BBB by specific active targeting between Exo, inheriting the lymphocyte function-associated antigen 1 (LFA-1) and endothelial intercellular adhesion molecule 1 (ICAM-1). Exosomes derived from curcumin-treated (primed) cells (Exo-cur) can better prevent the death of neurons in vitro and in vivo to relieve the symptoms of AD by inhibiting phosphorylation of the Tau protein through activating the AKT/GSK-3β pathway. Our results suggested that Exo-cur featured highly effective BBB-crossing via receptor-mediated transcytosis to access brain tissues and inhibited Tau phosphorylation, holding great potential in improving targeted drug delivery and the recovery of neuronal function in AD therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, it enhanced curcumin solubility, stability, and bioavailability, and curcumin exhibited a slow and smooth release profile.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Enhanced brain penetration via RMT was also observed, with a 6.5 times higher brain concentration compared to free curcumin.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Western plot analysis confirmed the inheritance of lymphocyte function-associated antigen 1 (LFA-1) from their parental cells, a protein that interacts with the endothelial intercellular adhesion molecule 1 (ICAM-1), used for BBB crossing.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“No significant cytotoxicity was reported; in vivo, higher hippocampus accumulation was observed, and a reduction in OA-induced neuronal injury, cytotoxicity, and tau phosphorylation was confirmed.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“The MWM test revealed an amelioration of learning and memory abilities by presenting shorter escape latencies, spatially oriented swimming behavior, and more time in the targeted quadrant.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
In the citing paper
“Finally, naïve exosomes also reduced OA-induced consequences and inhibited microglia activation and neuronal cell apoptosis.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [116]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Using exosomes, naturally-equipped nanocarriers, for drug delivery
Batrakova, E. V., & Kim, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.030 · Cited by 1,041
(2016) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 874
Flagged first, then by citations
Research works printed but not linked: 3
- M. Prince , A.Comas-Herrera , M.Knapp , M.Guerchet and M.Karagiannidou , in Proceedings of the World Alzheimer Report at Alzheimer's Disease International , London, UK , September, 2016
- Holtzman, 2011, Sci. Transl. Med., 3, 77sr1
- Johnsen, 2014, Biochim. Biophys. Acta, 1846, 75
Cited by
Sorted by citations
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W., Chen, C., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 642
Exosome engineering: Current progress in cargo loading and targeted delivery
Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100261 · Cited by 444
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 343
Chen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319
Curcumin Delivery Mediated by Bio-Based Nanoparticles: A Review
Nasery, M. M., Abadi, B., Poormoghadam, D., Zarrabi, A., Keyhanvar, P., Khanbabaei, H., Ashrafizadeh, M., Mohammadinejad, R., Tavakol, S., & Sethi, G. (2020) · Molecules · doi:10.3390/molecules25030689 · Cited by 291
M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization
Li, H., Feng, Y., Zheng, X. C., Jia, M., Mei, Z., Wang, Y., Zhang, Z., Zhou, M., & Li, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.019 · Cited by 266
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
Huda, M. N., Nafiujjaman, M., Deaguero, I. G., Okonkwo, J., Hill, M. L., Kim, T. H., & Nurunnabi, M. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00217 · Cited by 268
Qi, Y., Guo, L., Jiang, Y., Shi, Y., Sui, H., & Zhao, L. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1762262 · Cited by 239
Self-citationXiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Exosomes based strategies for brain drug delivery
Rehman, F. U., Liu, Y., Zheng, M., & Shi, B. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121949 · Cited by 240
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229
Self-citationA comprehensive review of challenges and advances in exosome-based drug delivery systems
Palakurthi, S. S., Shah, B. M., Kapre, S., Charbe, N. B., Immanuel, S., Pasham, S., Thalla, M., Jain, A., & Palakurthi, S. (2024) · Nanoscale Advances · doi:10.1039/d4na00501e · Cited by 255
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies
de Castilla, P. E. M., Tong, L., Huang, C., Sofias, A. M., Pastorin, G., Chen, X. S., Storm, G., Schiffelers, R. M., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.011 · Cited by 219
Liu, Q., Li, D., Pan, X., & Liang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02081-0 · Cited by 201
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease
Guo, M., Yin, Z., Chen, F., & Lei, P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00670-x · Cited by 205
Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases
Salehi, B., Călina, D. C., Docea, A. O., Koirala, N., Aryal, S., Lombardo, D., Pasqua, L., Taheri, Y., Castillo, C. M. S., Martorell, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020430 · Cited by 199
Ruan, S., Zhou, Y., Jiang, X., & Gao, H. (2021) · Advanced Science · doi:10.1002/advs.202004025 · Cited by 200
Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Martins, T. S., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., Silva, O. A. B. D. C. E., & Henriques, A. G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 177
Antioxidants Targeting Mitochondrial Oxidative Stress: Promising Neuroprotectants for Epilepsy
Yang, N., Guan, Q.-W., Chen, F., Xia, Q., Yin, X., Zhou, H.-H., & Mao, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6687185 · Cited by 161
Exosomes Engineering and Their Roles as Therapy Delivery Tools, Therapeutic Targets, and Biomarkers
Kučuk, N., Primožič, M., Knez, Ž., & Leitgeb, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179543 · Cited by 161
Exosome as drug delivery system: Current advancements
Sharma, V., & Mukhopadhyay, C. D. (2024) · Extracellular Vesicle · doi:10.1016/j.vesic.2023.100032 · Cited by 156
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Curcumin, Hormesis and the Nervous System
Scuto, M. C., Mancuso, C., Tomasello, B., Ontario, M. L., Cavallaro, A. S., Frasca, F., Maiolino, L., Salinaro, A. T., Calabrese, E. J., & Calabrese, V. (2019) · Nutrients · doi:10.3390/nu11102417 · Cited by 157
Genetic and Epigenetic Etiology Underlying Autism Spectrum Disorder
Yoon, S. H., Choi, J., Lee, W. Y., & Do, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040966 · Cited by 175
He, R., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111314 · Cited by 147
Self-citationHuo, L., Du, X., Li, X., Liu, S., & Xu, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.738442 · Cited by 149
Kooijmans, S. A. A., de Jong, O. G., & Schiffelers, R. M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.017 · Cited by 147
Guo, L., Huang, Z., Huang, L., Liang, J., Wang, P., Zhao, L., & Shi, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00879-4 · Cited by 134
Self-citationRecent progress in nanotechnology-based drug carriers for resveratrol delivery
Li, C., Wang, Z., Lei, H., & Zhang, D. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2174206 · Cited by 131
Recent progresses in exosome-based systems for targeted drug delivery to the brain
Bashyal, S., Chhitij, T., & Lee, S. K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.011 · Cited by 130
Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies
Mehdizadeh, S., Mamaghani, M., Hassanikia, S., Pilehvar‐Soltanahmadi, Y., & Ertaş, Y. N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03352-8 · Cited by 138
Azzini, E., Peña‐Corona, S. I., Hernández‐Parra, H., Chandran, D., Saleena, L. A. K., Sawikr, Y., Peluso, I., Dhumal, S., Kumar, M., Leyva‐Gómez, G., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8200 · Cited by 127
Kang, J.-Y., Kim, H., Mun, D., Yun, N., & Joung, B. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.018 · Cited by 104
Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy
Khatami, S. H., Karami, N., Taheri‐Anganeh, M., Taghvimi, S., Tondro, G., Khorsand, M., Fard, E. S., Sedighimehr, N., Kazemi, M., Jaberi, K. R., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03365-0 · Cited by 109
Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases
Nouri, Z., Barfar, A., Perseh, S., Motasadizadeh, H., Maghsoudian, S., Fatahi, Y., Nouri, K., Yektakasmaei, M. P., Dinarvand, R., & Atyabi, F. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02681-4 · Cited by 103
Novel concept of exosome-like liposomes for the treatment of Alzheimer's disease
Fernandes, M. S., Lopes, I., Magalhães, L., Sárria, M. P., Machado, R., Sousa, J. C., Botelho, C., Teixeira, J. A., & Gomes, A. C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.018 · Cited by 97
Li, S., Stöckl, S., Lukas, C., Herrmann, M., Brochhausen, C., König, M. A., Johnstone, B., & Grässel, S. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02317-6 · Cited by 96
The application of exosomes and Exosome-nanoparticle in treating brain disorders
Salarpour, S., Barani, M., Pardakhty, A., Khatami, M., & Chauhan, N. P. S. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118549 · Cited by 92
The role of PI3K signaling pathway in Alzheimer’s disease
Pan, J., Yao, Q., Wang, Y., Chang, S., Li, C., Wu, Y., Shen, J., & Yang, R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459025 · Cited by 89
Lipid-Based Nanovesicular Drug Delivery Systems
Limongi, T., Susa, F., Marini, M., Allione, M., Torre, B., Pisano, R., & Fabrizio, E. M. D. (2021) · Nanomaterials · doi:10.3390/nano11123391 · Cited by 90
Dietary nutrition for neurological disease therapy: Current status and future directions
Mao, X., Yin, X., Guan, Q.-W., Xia, Q., Yang, N., Zhou, H., Liu, Z., & Jin, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107861 · Cited by 85
Shetgaonkar, G. G., Marques, S. M., DCruz, C. E. M., Vibhavari, R. J. A., Kumar, L., & Shirodkar, R. K. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01026-0 · Cited by 400
Osaid, Z., Haider, M. A., Hamoudi, R., & Harati, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115635 · Cited by 89
Yuan, Y., Wang, J., Zhang, Y., Li, L., Reza, A. M. M. T., & Gurunathan, S. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s407029 · Cited by 85
Functional Extracellular Vesicles for Regenerative Medicine
Kim, H. Y., Kwon, S., Um, W., Shin, S., Kim, C. H., Park, J. H., & Kim, B. (2022) · Small · doi:10.1002/smll.202106569 · Cited by 81
Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies
Zheng, Q., Kebede, M. T., Kemeh, M. M., Islam, S., Lee, B., Bleck, S. D., Wurfl, L. A., & Lazo, N. D. (2019) · Molecules · doi:10.3390/molecules24122316 · Cited by 82
Extracellular Vesicles as Drug Transporters
Nowak, M., Górczyńska, J., Kołodzińska, K., Rubin, J., & Choromańska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210267 · Cited by 84
New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease
Ouyang, Q., Meng, Y., Zhou, W., Tong, J., Cheng, Z., & Zhu, Q. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1927055 · Cited by 80
Targetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer’s Disease
Yin, Q., Ji, X., Lv, R., Pei, J.-J., Du, Y., Shen, C., & Hou, X. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s240400 · Cited by 77
Chen, L., Liu, W., Lin, H., Lin, M., Yu, Y., Liu, H., Dai, Y., Chen, L.-W., Jia, W., He, X., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335832 · Cited by 76
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Liu, X., Zhong, X., & Li, C. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.03.015 · Cited by 73
Vassileff, N., Cheng, L., & Hill, A. F. (2020) · Journal of Cell Science · doi:10.1242/jcs.243139 · Cited by 73
Xu, C., Zhai, Z., Ying, H., Lü, L., Zhang, J., & Zeng, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01339-3 · Cited by 72
Lopes, D., Lopes, J., Pereira-Silva, M., Peixoto, D., Rabiee, N., Veiga, F., Moradi, O., Guo, Z.-H., Wang, X.-D., Conde, J., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00453-z · Cited by 36
Engineered extracellular vesicles as brain therapeutics
Lino, M. M., Simões, S., Tomatis, F., Albino, I., Barrera, A., Vivien, D., Sobrino, T., & Ferreira, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.037 · Cited by 68
Tian, C., Gao, L., & Zucker, I. H. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.013 · Cited by 67
Engineering of MSC-Derived Exosomes: A Promising Cell-Free Therapy for Osteoarthritis
Cheng, J., Sun, Y., Ma, Y., Ao, Y., Hu, X., & Meng, Q. (2022) · Membranes · doi:10.3390/membranes12080739 · Cited by 69
Huang, Z., Guo, L., Huang, L., Shi, Y., Liang, J., & Zhao, L. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112123 · Cited by 65
Self-citationThe Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
Iranpanah, A., Kooshki, L., Moradi, S. Z., Saso, L., Fakhri, S., & Khan, H. Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031006 · Cited by 68
TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications
Gu, Z., Cao, H., Zuo, C., Huang, Y., Miao, J., Song, Y., Yang, Y., Zhu, L., & Wang, F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105855 · Cited by 69
Isolation and usage of exosomes in central nervous system diseases
Wang, W., Sun, H., Duan, H., Sheng, G., Tian, N., Liu, D., & Sun, Z. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14677 · Cited by 62
Yang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63
“Hao Wang’s team designed exosomes carrying curcumin (cur) to enable curcumin to cross the blood-brain barrier (BBB) and inhibit the phosphorylation of tau protein by activating the AKT/GSK-3 β pathway, better preventing neuronal death in vivo and in vitro and alleviating AD symptoms [187].”
BackgroundPayandeh, Z., Tangruksa, B., Synnergren, J., Heydarkhan‐Hagvall, S., Nordin, J. Z., Andaloussi, S. E., Borén, J., Wiseman, J., Bohlooly‐Y, M., Lindfors, L., et al. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101302 · Cited by 70
Diagnostic and Therapeutic Potential of Exosomes in Neurodegenerative Diseases
Gao, P., Li, X., Du, X., Liu, S., & Xu, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.790863 · Cited by 61
The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system
Jiang, X., Zhang, T., & Gao, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114324 · Cited by 61
Fan, Y., Li, Y., Huang, S., Xu, H., Li, H., & Liu, B. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135262 · Cited by 59
Li, F., Zhao, L., Shi, Y., & Liang, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00245 · Cited by 58
Self-citationHuo, Q., Shi, Y., Qi, Y., Huang, L., Sui, H., & Zhao, L. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2021.112365 · Cited by 58
Self-citationExtracellular Vesicles in Mental Disorders: A State-of-art Review
Kong, L., Zhang, D., Huang, S., Lai, J., Lü, L., Zhang, J., & Hu, S. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79666 · Cited by 59
Wang, R., Zhang, Y., Guo, Y., Zeng, W., Li, J., Wu, J. J., Li, N., Zhu, A., Li, J., Di, L., et al. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.09.007 · Cited by 60
Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects
Cheng, Z., Han, T., Yao, J., Wang, K., Dong, X., Fan, Y., Huang, H., Han, M., Liao, Q., He, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116065 · Cited by 58
Transcription factor EB: an emerging drug target for neurodegenerative disorders
Song, J., Liu, J., Jiang, Y., Wang, Z., & Li, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.013 · Cited by 59
Self-citationGomes, P., Tzouanou, F., Skolariki, K., Vamvaka-Iakovou, A., Nogueras‐Ortiz, C. J., Tsirtsaki, K., Waites, C. L., Vlamos, P., Sousa, N., Costa‐Silva, B., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114183 · Cited by 60
Syed, M. H., Zahari, M. A. K. M., Khan, M. M. R., Beg, M. D. H., & Abdullah, N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104121 · Cited by 57
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
Zhang, X., Lai, K., Li, S., Wang, J., Li, J., Wang, W., Ni, S., Lu, B., Grzybowski, A. E., Ji, J., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.015 · Cited by 53
Wang, Y., Wang, J., Liu, C., Li, J., Lu, K., Yu, Q., Zhang, Y., & Shen, Z. (2023) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2023.06.005 · Cited by 51
Kodidela, S., Gerth, K. A., Haque, S., Gong, Y., Ismael, S., Singh, A. K., Ishrat, T., & Kumar, S. (2019) · Cells · doi:10.3390/cells8090968 · Cited by 51
Extracellular vesicles in neurodegenerative diseases: Insights and new perspectives
Yuan, Q., Li, X., Zhang, S.-M., Wang, H., & Wang, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.001 · Cited by 60
Self-citationMarkoutsa, E., Mayilsamy, K., Gulick, D., Mohapatra, S. S., & Mohapatra, S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.008 · Cited by 52
Reynolds, J. L., & Mahajan, S. D. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09895-6 · Cited by 49
Emerging prospects of extracellular vesicles for brain disease theranostics
Wang, R., Wang, X., Zhang, Y., Zhao, H., Cui, J., Li, J., & Di, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.024 · Cited by 48
Edible plant extracellular vesicles: An emerging tool for bioactives delivery
Fan, S., Chen, J., Tang, C.-H., Zhao, Q., Zhang, J., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028418 · Cited by 53
Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review
Silva, D. F., Melo, A. L. P., Uchôa, A. F. C., Pereira, G. M. A., Alves, Á. E. F., Vasconcellos, M. C., Júnior, F. H. X., & Passos, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316719 · Cited by 53
Exosomes as Carriers for Drug Delivery in Cancer Therapy
Zeng, W., Wen, Z., Chen, H., & Duan, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03224-y · Cited by 48
Li, J., Long, Q., Ding, H., Wang, Y., Luo, D., Li, Z., & Zhang, W. (2024) · Advanced Science · doi:10.1002/advs.202308677 · Cited by 47
Susa, F., Arpicco, S., Pirri, C. F., & Limongi, T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070849 · Cited by 50
Engineered Exosomes as Smart Drug Carriers: Overcoming Biological Barriers in CNS and Cancer Therapy
Premchandani, T., Tatode, A., Taksande, J., Umekar, M. J., Qutub, M., Hussain, U., & Singanwad, P. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020019 · Cited by 54
Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
Chu, J., Zhang, W., Liu, Y., Gong, B., Ji, W., Yin, T., Gao, C., Liangwen, D., Hao, M., Chen, C., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374137 · Cited by 48
Brain Exosomes: Friend or Foe in Alzheimer’s Disease?
Kaur, S., Verma, H., Dhiman, M., Tell, G., Gigli, G. L., Janes, F., & Mantha, A. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02547-y · Cited by 45
Loch-Neckel, G., Matos, A. T., Vaz, A. R., & Brites, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.839790 · Cited by 46
Dieckol Ameliorates Aβ Production via PI3K/Akt/GSK-3β Regulated APP Processing in SweAPP N2a Cell
Yoon, J.-H., Lee, N., Youn, K., Jo, M. R., Kim, H., Lee, D., Ho, C., & Jun, M. (2021) · Marine Drugs · doi:10.3390/md19030152 · Cited by 46
From blood to brain: blood cell-based biomimetic drug delivery systems
Li, Y., Wu, J., Liu, J., Qiu, X., Xu, W., Tang, T., & Xiang, D. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937384 · Cited by 46
Wu, X., Zheng, X., Tang, H., Zhao, L., He, C., Zou, Y., Song, X., Li, L., Yin, Z., & Ye, G. (2022) · Medicine · doi:10.1097/md.0000000000030194 · Cited by 48
Self-citationExtracellular vesicle-associated lipids in central nervous system disorders
Vanherle, S., Haidar, M., Irobi, J., Bogie, J. F. J., & Hendriks, J. J. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.011 · Cited by 45
Rather, H., Almousa, S., Craft, S., & Deep, G. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102088 · Cited by 45
Recent Advances on Extracellular Vesicles in Central Nervous System Diseases
Jin, T., Gu, J., Li, Z., Xu, Z., & Gui, Y. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s288415 · Cited by 44
Metadata
- Authors
- Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L.
- Affiliations
- Jinzhou Medical University (CN)
- Corresponding author
- Shi, Yijie
- Liang, Jia
- Zhao, Liang
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 11
- Issue
- 15
- Pages
- 7481-7496
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W2923362583
- Cited by
- 324
- References
- 48
- Citations by year
- 2026: 26 · 2025: 51 · 2024: 48 · 2023: 63 · 2022: 45 · 2021: 51 · 2020: 32 · 2019: 8
- FWCI
- 23.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanoscale (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81501017, 81502484)
- Natural Science Foundation of Liaoning Province (201602337)
- Department of Education of Liaoning Province (JYTQN201719)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Keywords
- curcumin, exosomes, Alzheimer's disease, tau hyperphosphorylation, blood-brain barrier penetration, transcytosis, drug delivery, neuronal cell death, cognitive function
- MeSH terms
- RAW 264.7 Cells, Glycogen Synthase Kinase 3 beta, Alzheimer Disease, Animals, Cognition, Curcumin, Disease Models, Animal, Drug Carriers, Male, Phosphorylation, tau Proteins, Rats, Sprague-Dawley, Proto-Oncogene Proteins c-akt, Mice, Rats, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
